Next Article in Journal
Cross-Canada Differences in Early-Stage Breast Cancer Treatment and Acute-Care Use
Previous Article in Journal
Descriptive Analysis of Dosing and Outcomes for Patients with Ibrutinib-Treated Relapsed or Refractory Chronic Lymphocytic Leukemia in a Canadian Centre
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 26
Issue 5
10.3747/co.26.5235
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

OCTANE (Ontario-Wide Cancer Targeted Nucleic Acid Evaluation): A Platform for Intraprovincial, National, and International Clinical Data-Sharing

by
E. R. Malone
1,
R. R. Saleh
1,
C. Yu
1,
L. Ahmed
1,
T. Pugh
1,
J. Torchia
1,
J. Bartlett
1,
C. Virtanen
1,
S. J. Hotte
2,
J. Hilton
3,
S. Welch
4,
A. Robinson
5,
E. McCready
2,
B. Lo
3,
B. Sadikovic
4,
H. Feilotter
5,
T. P. Hanna
5,
S. Kamel-Reid
1,
T. L. Stockley
1,
L. L. Siu
1 and
Philippe L. Bedard
1,*add Show full author list remove Hide full author list
1
cess Margaret Cancer Centre, Division of Medical Oncology and Hematology, 700 University Avenue, 7-723, Toronto, ON M5G 1Z5, Canada
2
Laboratory Genetic Services Division, Hamilton Regional Laboratory Medicine Program, Hamilton, ON, Canada
3
The Ottawa Hospital Research Institute, Ottawa, ON, Canada
4
Department of Pathology and Laboratory Medicine, Western University, and Molecular Genetics Laboratory, Molecular Diagnostics Division, London Health Sciences Centre, London, ON, Canada
5
Department of Pathology and Molecular Medicine, Queen’s University, Kingston, ON, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2019, 26(5), 618-623; https://doi.org/10.3747/co.26.5235
Submission received: 14 July 2019 / Revised: 10 August 2019 / Accepted: 5 September 2019 / Published: 1 October 2019

Abstract

Cancer is a genetic disease resulting from germline or somatic genetic aberrations. Rapid progress in the field of genomics in recent years is allowing for increased characterization and understanding of the various forms of the disease. The Ontario-wide Cancer Targeted Nucleic Acid Evaluation (octane) clinical trial, open at cancer centres across Ontario, aims to increase access to genomic sequencing of tumours and to facilitate the collection of clinical data related to enrolled patients and their clinical outcomes. The study is designed to assess the clinical utility of next-generation sequencing (ngs) in cancer patient care, including enhancement of treatment options available to patients. A core aim of the study is to encourage collaboration between cancer hospitals within Ontario while also increasing international collaboration in terms of sharing the newly generated data. The single-payer provincial health care system in Ontario provides a unique opportunity to develop a province-wide registry of ngs testing and a repository of genomically characterized, clinically annotated samples. It also provides an important opportunity to use province-wide real-world data to evaluate outcomes and the cost of ngs for patients with advanced cancer. The octane study is attempting to translate knowledge to help deliver precision oncology in a Canadian environment. In this article, we discuss the background to the study and its implementation, current status, and future directions.
Keywords: Medical oncology; clinical trials; basket studies; precision medicine Medical oncology; clinical trials; basket studies; precision medicine

Share and Cite

MDPI and ACS Style

Malone, E.R.; Saleh, R.R.; Yu, C.; Ahmed, L.; Pugh, T.; Torchia, J.; Bartlett, J.; Virtanen, C.; Hotte, S.J.; Hilton, J.; et al. OCTANE (Ontario-Wide Cancer Targeted Nucleic Acid Evaluation): A Platform for Intraprovincial, National, and International Clinical Data-Sharing. Curr. Oncol. 2019, 26, 618-623. https://doi.org/10.3747/co.26.5235

AMA Style

Malone ER, Saleh RR, Yu C, Ahmed L, Pugh T, Torchia J, Bartlett J, Virtanen C, Hotte SJ, Hilton J, et al. OCTANE (Ontario-Wide Cancer Targeted Nucleic Acid Evaluation): A Platform for Intraprovincial, National, and International Clinical Data-Sharing. Current Oncology. 2019; 26(5):618-623. https://doi.org/10.3747/co.26.5235

Chicago/Turabian Style

Malone, E. R., R. R. Saleh, C. Yu, L. Ahmed, T. Pugh, J. Torchia, J. Bartlett, C. Virtanen, S. J. Hotte, J. Hilton, and et al. 2019. "OCTANE (Ontario-Wide Cancer Targeted Nucleic Acid Evaluation): A Platform for Intraprovincial, National, and International Clinical Data-Sharing" Current Oncology 26, no. 5: 618-623. https://doi.org/10.3747/co.26.5235

APA Style

Malone, E. R., Saleh, R. R., Yu, C., Ahmed, L., Pugh, T., Torchia, J., Bartlett, J., Virtanen, C., Hotte, S. J., Hilton, J., Welch, S., Robinson, A., McCready, E., Lo, B., Sadikovic, B., Feilotter, H., Hanna, T. P., Kamel-Reid, S., Stockley, T. L., ... Bedard, P. L. (2019). OCTANE (Ontario-Wide Cancer Targeted Nucleic Acid Evaluation): A Platform for Intraprovincial, National, and International Clinical Data-Sharing. Current Oncology, 26(5), 618-623. https://doi.org/10.3747/co.26.5235

Article Metrics

Back to TopTop